Replies to post #6349 on Revance Therapeutics Inc (RVNC)

[PioneerUniverse8]

If it is truly just 40% of what Botox brings per CD patient then adoption will be much faster than 50% by EOY '25.

[DewDiligence]

Re: Addressable market for CD and other movement disorders

You’re overlooking the opportunity with treatment-naïve cervical-dystonia and movement-disorder patients who opt for treatment with botulinum toxin because there is now a product that provides sufficient symptom relief. Many neurologists probably don’t think Botox is worth the trouble for some of their patients because of the gaps in symptom relief between injections.